The company stated at the shareholder meeting they would need to raise money. This is obvious. My question directly to them was whether or not they were going to dilute the "pants" off shareholders. They said no. They said they are rolling LaViv out slowly and methodically so raising a ton of money was not something they needed to do. The process is so unique and specialized, it must be done carefully. As the company grows, they will add capacity and do what they need to do to ensure supply keeps up with demand. I think once you see the warrant conversion come to an end July 7 and perhaps some clarity on how the company plans to raise additional monies, the stock will rebound nicely. The risk/reward is good.
La Viv is a natural substance, unlike Botox which is synthetic. We all know of the terrible reactions many have had with Botox. Will LaViv completely replace Botox? Doubtful. There will be demand for Botox. LaViv is somewhat of an alternative to Botox. I think there will be a decent size of the population that would rather try something that is natural, works better and lasts longer than go for something that could be dangerous. After all, we are talking about wrinkles. Why risk your health to clear up some wrinkles? I wouldn't take a chance. And let's not forget acne scarring which could be approved within 1+ years. Perhaps this will be fast tracked. If the FDA approved LaViv for wrinkles, why wouldn't they approve it for acne scarring. This could be a big money marker for the company. In addition, the company has assembled a pretty impressive board. Dr. Langer is an accomplished and recognized doctor, Pernock was high up in the ranks at Glaxo. Novak worked at the FDA. I think there is another member of the board who use to work for Glaxo too. Not bad.
"Don't worry about the world coming to an end today. It's already tomorrow in Australia"
Market Data 
Markets 
